We are live on ! Find out more

Telomir Pharmaceuticals

TELO

Market cap $83.9M

1.22 USD

+0.01

0.83%

At close Updated Sep 25, 9:47 AM EDT

1 day

0.83%

5 days

-0.81%

1 month

3.39%

3 months

-0.81%

6 months

-8.27%

Year to date

-8.96%

1 year

-12.86%

5 years

-75.6%

10 years

-75.6%

About: Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced the peer-reviewed publication of new preclinical research showing that Telomir-Zn significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD).

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma models.

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL / ACCESS Newswire / June 15, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity and significant improvement in glucose homeostasis with Telomir-Zn in a diet-induced zebrafish model of Type 2 diabetes mellitus (T2DM).

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model. MIAMI, FL / ACCESS Newswire / May 20, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the peer-reviewed publication of preclinical data showing that Telomir-Zn produced dose-dependent survival improvement across multiple endpoints in a Wilson's disease model, supporting the biological activity of Telomir-Zn in Wilson's disease.

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its lead candidate, Telomir-Zn, for the treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC).

Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newswire / April 24, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related diseases, today announced the successful closing of its previously announced acquisition of TELI Pharmaceuticals, Inc. ("TELI").

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate, Telomir-1 (Telomir-Zn), for the treatment of advanced and metastatic Triple-Negative Breast Cancer (TNBC).

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic drivers of cancer, today announced new in vitro data demonstrating that Telomir-1 (Telomir-Zn) induces broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer (TNBC).

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental biological mechanisms implicated in cancer, aging, and degenerative disease, today announced new cellular study results demonstrating that Telomir-1, in the form of Telomir-Zn, induces a rapid and coordinated intracellular redistribution of zinc and iron.

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

See News Rankings

Price charts implemented using Lightweight Charts™